Early diagnosis is crucial for the successful treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer in adults and the sixth most common cancer worldwide.
Learn more about HCC here: https://t.co/hwO0s2vJLM pic.twitter.com/J92ezPKHcX
— Ipsen (@IpsenGroup) August 13, 2020
We empower our people to make decisions in the best interest of patients, and we're committed to building bridges to ensure all patients receive excellent care. Learn more about our promise: https://t.co/P9thujPMtn pic.twitter.com/6PV2CO7mnL
— Ipsen (@IpsenGroup) August 10, 2020
Despite a challenging first half of 2020, we’re happy to announce 3.1% growth in Group sales thanks to our team’s incredible commitment to patients. For more details, read the article here #IPN #financialresults https://t.co/3QZSoPNtny pic.twitter.com/kRbDjLylAP
— Ipsen (@IpsenGroup) July 30, 2020
For patients with #spasticity associated with stroke, traumatic brain injury, or spinal cord injury, the reappearance of symptoms can impact at least 17 areas of day-to-day life.
— Ipsen (@IpsenGroup) July 28, 2020
— Ipsen (@IpsenGroup) July 25, 2020
For patients living with #cervicaldystonia, treatment impact on quality of life can be a roller coaster. Learn more from a recent survey:
— Ipsen (@IpsenGroup) July 14, 2020
We’re supporting COR2ED and @WAPO_org to understand the challenges facing patients living with #acromegaly, so we can provide them with the support they need. Read more from Dr. Abdelali (Ali) Majdi, our Head of Global Medical Affairs (Rare Diseases): https://t.co/JpqkodsH08 pic.twitter.com/6MxNOQ5bi1
— Ipsen (@IpsenGroup) July 7, 2020
Ipsen is pleased to announce a collaboration with @ExelixisInc and @Roche to evaluate a novel treatment approach for metastatic non-small cell lung cancer and metastatic castration-resistant #prostatecancer. Read the press release https://t.co/kKlcHtSfUX pic.twitter.com/El4UJ8677G
— Ipsen (@IpsenGroup) July 2, 2020
Today, we’re pleased to publish our 2019 Annual Report. With our most robust R&D pipeline yet, continued financial growth and our first materiality matrix assessment for CSR, 2019 was a pivotal year for Ipsen.
— Ipsen (@IpsenGroup) June 12, 2020
We’re excited to announce that the Natural History Study of fibrodysplasia ossificans progressiva (#FOP) has been published in the Journal of the Endocrine Society. It’s the first global, multicenter study designed to measure disease progression in #FOP over 3 years.
— Ipsen (@IpsenGroup) June 11, 2020
Ipsen, together with @Sanofi and @Servier, are proud to support @GlobalYouthIGF movement, who are running a campaign with @ASOP_Europe to educate young people about the risks of fake medicines online, particularly during the COVID-19 pandemic. Join us! #WACDay2020
— Ipsen (@IpsenGroup) June 10, 2020
We’ve shared eight new abstracts, accepted at #ENDO2020 and published in the Journal of the Endocrine Society. These abstracts demonstrate our commitment to patients with rare diseases such as fibrodysplasia ossificans progressiva (#FOP) and #Acromegaly.
— Ipsen (@IpsenGroup) June 8, 2020
— Ipsen (@IpsenGroup) June 1, 2020
For #cervicaldystonia patients, a recent survey uncovered that between treatments, the most common recurring symptoms experienced are muscle spasms, pain and involuntary movement.
— Ipsen (@IpsenGroup) May 25, 2020
— Ipsen (@IpsenGroup) May 21, 2020
Mass. ranks as second most innovative US state, according to Bloomberg index. https://t.co/vmPU8zrdPE
— Ipsen Innovation Center BioLabs (@BioLabsIPSEN) July 2, 2020
— BioLabs Boston (@BioLabsBoston) July 20, 2020
— BioLabs (@biolabs) November 4, 2019
While the full impact of the pandemic remains unknown, one thing remains abundantly clear — #cancer doesn’t wait. Hear from Richard Paulson, CEO, North America, on why we won’t wait either.
— IpsenUS (@IpsenUS) August 6, 2020
— IpsenUS (@IpsenUS) July 1, 2020
— IpsenUS (@IpsenUS) May 28, 2020
New botulinum neurotoxin-related structures in the August issue!
High‐resolution crystal structures of the botulinum neurotoxin binding domains from subtypes A5 and A6 https://t.co/BIqyxmVsGW#structuralbiology #botulinum@UniofBathSci @UniofBath @Stockholm_Uni @IpsenGroup pic.twitter.com/1ezs0TL5zl
— FEBS Open Bio (@FEBSOpenBio) August 11, 2020
We'd like to thank our exhibitors & sponsors. #has2020 @CVSHealth @AstraZenecaUS @EisaiUS @medicomhealth @CoverMyMeds @MyGoodDays @NCPDP @TailorMedTweet @JanssenUS @AssistanceFund @VivorHQ @genentech @HealthWellOrg @CancerCare @bmsnews @IpsenUS @EzscriptRx @PAN_Foundation pic.twitter.com/lfSZsWvcqn
— Healthcare Advocate Summit (@AdvocateSummit) March 5, 2020
The Servier @ParisSaclay Research Institute represents a major step for the Servier Group in achieving a more open, dynamic and #productive #research to serve #patient needs https://t.co/8TEh14tohw pic.twitter.com/N7QFnptNya
— Servier (@Servier) July 27, 2020
The Servier @ParisSaclay Research Institute will enable Servier teams to accelerate #projects decision-making, boost the group’s #partnerships dynamic and explore new ways of #working. https://t.co/9mXiIjFReT pic.twitter.com/8jZm9irQQ8
— Servier (@Servier) July 24, 2020
— Servier (@Servier) July 2, 2020
— Servier (@Servier) June 12, 2020
The falsification of #medicines has reached worrying levels in recent years and affects every country. Together, let's fight against counterfeit medicines. “We Rely on You, We Rely on Youth” for combating #fakemeds. #WACDay2020 @GlobalYouthIGF @ASOP_Europe https://t.co/uXvJrxHvq9
— Servier (@Servier) June 10, 2020
Servier China received an award by the Cross-Straits Medicine Exchange Association and the Beijing Community Health Promotion Association for its involvement in the fight against #COVID19. Our subsidiary released funds and donated materials to help fight the COVID19 epidemic. pic.twitter.com/Qf6T2hg8Sx
— Servier (@Servier) June 9, 2020
— Servier (@Servier) June 2, 2020
— Servier (@Servier) May 29, 2020
Today is #ICTD2020! Essential for improving the prevention, diagnosis, and treatment of diseases, our teams had to adapt to the #COVID19 context. Lydie Poitout, Head of Clinical Trial Management, explains how the Servier Group has adapted to the situationhttps://t.co/QkdmVF9y9D
— Servier (@Servier) May 20, 2020
[#WorldLupusDay]: Doctors' associations recommend that #patients with #lupus should not stop their #treatment without medical advice, especially in the context of the current #Covid19 crisis. https://t.co/yzMLi6yCpu pic.twitter.com/CRwXdHlipB
— Servier (@Servier) May 10, 2020
Could a smart t-shirt help patients manage chronic conditions?
— MPN Magazine (@MPN_Magazine) July 28, 2020
— Ventura's Lab (@PPMC_UAB) July 14, 2020
Check out the 2020 Biopharmaceutical @GBReports feature on Eric Falcand, @Servier VP, Head of Business Development & Licensing. Eric discusses our R&D efforts, growing footprint and how we're partnering to advance new therapies. Read more here: https://t.co/C5SrXP7FNK #oncology
— Servier Pharmaceuticals (@ServierPharma) June 16, 2020
— The Science Advisory Board (@ScienceBoard) June 16, 2020
This week the spotlight is on Vassilis Georgiadis – our Principal Partnerships Manager (Pharma & Healthcare)– who talked about his work on a partnership between @UCL and international pharmaceutical company @Servier on immuno-inflammatory disease research. https://t.co/Z0HHiSuCYr
— UCL Innovation & Enterprise (@UCLEnterprise) May 23, 2020
#COVID19 demands an extraordinary level of flexibility to find solutions tailored to each study and each patient. @servier explains how they adapted to the situation to ensure patients safety and continuity of #clinicaltrials #ICTD2020 #WeWontRest https://t.co/X01qmyz2Fj pic.twitter.com/nXARLp9879
— EFPIA (@EFPIA) May 20, 2020
.@Servier contributes to the fight against #COVID19
✅Working in partnership with other organisations to develop innovative solutions to help patients
✅Ensuring the supply of medicines
✅Supporting solidarity initiatives in 35+ countries#WeWontRest https://t.co/blwAZrE3Q6 pic.twitter.com/ImHTIKNTlz
— EFPIA (@EFPIA) May 12, 2020